Abeona Therapeutics (ABEO) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

Fundamental rating is neutral with a 5.1/10 score. Strengths include cash‑to‑market value, inventory turnover and fixed‑asset efficiency; weaknesses lie in asset‑to‑market, revenue‑to‑market gaps and low gross margin. Overall, the company shows moderate financial health.

Analysis Checks(6/10)

Revenue-MV

Value-2.12

Score1/3

Weight14.02%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.62%

1M Return1.54%

Inventory turnover ratio

Value0.56

Score3/3

Weight18.60%

1M Return6.74%

Gross profit margin (%)

Value73.68

Score1/3

Weight-1.32%

1M Return-0.63%

PB-ROE

Value0.11

Score3/3

Weight29.17%

1M Return9.74%

Income tax / Total profit (%)

Value0.14

Score1/3

Weight-1.07%

1M Return-0.50%

Fixed assets turnover ratio

Value0.53

Score3/3

Weight2.40%

1M Return1.06%

Cost of sales ratio (%)

Value26.32

Score3/3

Weight10.76%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight7.30%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight16.52%

1M Return5.94%

Is ABEO fundamentally strong?

ABEO scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its 70.05% ROE, 0.00% net margin, 3.86 P/E ratio, 1.73 P/B ratio, and 186.45% earnings growth, these metrics solidify its Netural investment rating.